Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-08
2009-02-24
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C530S326000, C530S327000
Reexamination Certificate
active
07494979
ABSTRACT:
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
REFERENCES:
patent: 5140102 (1992-08-01), Currie
patent: 5395490 (1995-03-01), Hoff et al.
patent: 5489670 (1996-02-01), Currie et al.
patent: 5879656 (1999-03-01), Waldman
patent: 5962220 (1999-10-01), Waldman
patent: 5969097 (1999-10-01), Wiegand et al.
patent: 6060037 (2000-05-01), Waldman
patent: 6586403 (2003-07-01), Mathison et al.
patent: 2003/0073628 (2003-04-01), Shailubhai et al.
patent: 2003/0232013 (2003-12-01), Siechman et al.
patent: 2004/0121961 (2004-06-01), Masferrer
patent: 2004/0152868 (2004-08-01), Larsen et al.
patent: 2004/0258687 (2004-12-01), Waldman et al.
patent: 2004/0266989 (2004-12-01), Currie et al.
patent: 2005/0032684 (2005-02-01), Cetin et al.
patent: 2006/0094658 (2006-05-01), Currie et al.
patent: 1012188 (2000-06-01), None
patent: WO 99/14239 (1999-03-01), None
patent: WO 01/25266 (2001-04-01), None
patent: WO 02/062369 (2002-08-01), None
patent: WO 02/078683 (2002-10-01), None
patent: WO 02/079235 (2002-10-01), None
patent: WO 02/098912 (2002-12-01), None
patent: WO 03/072125 (2003-09-01), None
patent: WO 2004/071436 (2004-08-01), None
patent: WO2006/001931 (2006-01-01), None
ExPASy PeptideCutter. internet document <<http://ca.expasy.org/tools/peptidecutter/peptidecutter—enzymes/html>>. Last updated Mar. 26, 2007, accessed Jun. 13, 2007; 12 pages.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; <http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm>; 5 pages.
S. Yuge et al. J. Biol. Chem. (2003) 278(25), pp. 22726-22733.
Amarante et al., “The k-opioid agonist (±)-bremazocine elicits peripheral antinociception by activation of the L-arginine
itric oxide/cyclic GMP pathway”European Journal of Pharmacology, vol. 454: pp. 19-23 (2002).
Arita et al., “Purification and characterization of a heat-stable enterotoxin ofVibrio mimicus” FEMS Microbiology Letters, vol. 79/1: pp. 105-110 (1991).
Chan et al., “Amino Acid Sequence of Heat-stable Enterotoxin Produced byEscherichia coliPathogenic for Man”The Journal of Biological Chemistry, vol. 256, No. 15: pp. 7744-7746 (1981).
Forte et al., “Lymphoguanylin: Cloning and Characterization of a Unique Member of the Guanylin Peptide Family”Endocrinology, vol. 140, No. 4: pp. 1800-1806 (1999).
Giannela, “Escherichia coliheat-stable enterotoxins, guanylins, and their receptors: What are they and what do they do?”The Journal of Laboratory and Clinical Medicine, vol. 125, No. 2: pp. 173-181 (1995).
Gualillo et al., “Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action”FEBS Letters, vol. 552: pp. 105-109 (2003).
Guarino et al., “Citrobacter freundii Produces an 18-Amino-Acid Heat-Stable Enterotoxin Identical to the 18-Amino-AcidEscherichia coliHeat-Stable Enterotoxin (ST Ia)”Infection and Immunity, vol. 57, No. 2: pp. 649-652 (1989).
Huang et al., “Nucleotide sequence of a gene encoding the novelYersinia enterocoliticaheat-stable enterotoxin that includes a pro-region-like sequence in its mature toxin molecule”Microbial Pathogenesis, vol. 22: pp. 89-97 (1997).
Jain et al., “Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway”Brain Research, vol. 909: pp. 170-178 (2001).
Kim et al., “Changes in ghrelin and ghrelin receptor expression according to feeding status”NeuroReport, vol. 14, No. 10: pp. 1317-1320 (2003).
Lazaro-Ibanez et al., “Participation of the nitric oxide-cyclic GMP-ATP-sensitive K+channel pathway in the antinociceptive action of ketorolac”European Journal of Pharmacology, vol. 426: pp. 39-44 (2001).
Moseley et al., “Isolation and Nucleotide Sequence Determination of a Gene Encoding a Heat-Stable Enterotoxin ofEscherichia coli” Infection and Immunity, vol. 39, No. 3: pp. 1167-1174 (1983).
Nzegwu et al., “Luminal capsaicin inhibits fluid secretion induced by exterotoxinE. coliSTa, but not by carbachol, in vivo in rat small and large intestines”Experimental Physiology, vol. 81, No. 2: pp. 313-315 (1996).
Rolfe et al., “EnterotoxinEscherichia coliSTa activates a nitric oxide-dependent myenteric plexus secretory reflex in the rat ileum”The Journal of Physiology, vol. 475, No. 3: pp. 531-537 (1994).
Rolfe et al., “Vagotomy inhibits the jejunal fluid secretion activated by luminal ilealEscherichia coliSTa in the rat in vivo”Gut, vol. 44: pp. 615-619 (1999).
Shailubhai, “Therapeutic applications of guanylate cyclase-C receptor agonists”Drug Discovery&Development, vol. 5 No. 2: pp. 261-268 (2002).
So et al., “Nucleotide Sequence of the Bacterial Transposon Tn1681 Encoding a Heat-Stable (ST) Toxin and Its Identification of EnterotoxigenicEscherichia coliStrains”Proceedings of the National Academy of Sciences of the U.S.A.., vol. 77, No. 7 [Part 2: Biological Sciences]: pp. 4011-4015 (1980).
Soares, et al., “Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K+channels in the Rat PGE2-induced hyperalgesic paw”British Journal of Pharmacology, vol. 134: pp. 127-131 (2001).
Takao et al., “Amino acid sequence of heat-stable enterotoxin produced byVibrio choleraenon-01”FEBS), vol. 193, No. 2: pp. 250-254 (1985).
Takao et al., “Isolation, primary structure and synthesis of heat-stable enterotoxin produced byYersinia enterocolitica” European Journal of Biochemistry, vol. 152, No. 1: pp. 199-206 (1985).
Vaandrager et al., “Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C”Molecular and Cellular Biochemistry, vol. 230, Nos. 1&2: pp. 73-83 (2002).
GenBank Accession No. QHECIB; GI:69638; Aimoto et al., Jun. 18, 1999.
GenBank Accession No. P01559; GI:123711; So et al., Oct. 25, 2004.
GenBank Accession No. AAA24653; GI:147878; Sekizaki et al., Apr. 26, 1993.
GenBank Accession No. P01560; GI:123707; Chan et al., Jun. 15, 2004.
GenBank Accession No. AAA27561; GI:295439; Ogawa et al., Jun. 12, 1993.
GenBank Accession No. P04429; GI:123712; Ogawa et al., Jun. 15, 2004.
GenBank Accession No. S34671; GI:421286; Rossolini et al., Apr. 12, 1995.
GenBank Accession No. CAA52209; GI:395161; Guglielmetti et al;, Jul. 27, 1995.
GenBank Accession No. A54534; GI:628844; Arita et al., May 3, 1996.
GenBank Accession No. AAL02159; GI:15592919; Teixeira et al., Sep. 13, 2001.
GenBank Accession No. AAA18472; GI:487395; Mikulskis et al., May 26, 1994.
GenBank Accession No. S25659; GI:282047; Takao et al., Oct. 15, 1999.
GenBank Accession No. P74977; GI:3913874; Ramamurthy et al., Jun. 15, 2004.
GenBank Accession No. BAA23656; GI:2662339; Huang et al., Feb. 13, 1999.
GenBank Accession No. P31518; GI:399947; Ibrahim et al., Mar. 15, 2004.
GenBank Accession No. P07965; GI:3915589; Stieglitz et al., Jun. 15, 2004.
Schulz et al., “Side chain contributions to the interconversion of the topological isomers of guanylin-like pepti
Currie Mark G.
Kurtz Caroline
Mahajan-Miklos Shalina
Sun Li Jing
Fish & Richardson P.C.
Ironwood Pharmaceuticals, Inc.
Kosar Andrew D
LandOfFree
Method for treating congestive heart failure and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating congestive heart failure and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating congestive heart failure and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085015